Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma
View
Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)
Indication:
Biliary Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
View
Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)
Indication:
Biliary Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II/III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Blood Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
FLEX Registry: Evaluate New Gene Express
View
Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Title:
Ph3 GDC0077+Palbo+Fulv vs Placebo PIK3CA
View
Description: A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT HOROMONE RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO41554)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph3 HR+/HER2- BC (OVELIA)
View
Description: A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 AZD9833 +Palb vs Anas ER+ HER2- BC (SERENA-4)
View
Description: SERENA-4: A Randomised Multicentre Double-Blind Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (D8532C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 T-DXd Pert vs Tax Trans Pert HER2+BC (DESTINY-09)
View
Description: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)(D967UC00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 Nira Her2- triple- BC ctDNA (ZEST)
View
Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 LY3484356 ER+ HER2- BC
View
Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant InvestigatorÂ's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 HER2+/ER+ BC
View
Description: A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 DAto-DXd PD1/PD L1 BC (TROPION Breast02)
View
Description: D926PC00001: A Phase III Open-label Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02).
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 Sac GOv vs PC BC (ASCENT-03)
View
Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 Imlun vs Endo ER+ HER2- BC
View
Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
View
Description: A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
Indication:
Breast Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC
View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR: Ph2 TT-00420 Advanced Cholangiocarcinoma
View
Description: A Phase II Open Label Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients with Advanced Cholangiocarcinoma (TT420C1206)
Indication:
Carcinoid
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
STAR Ph3 MRTX849 Cetux KRAS G12C CC
View
Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph1b AMG 510 MVASI Combo KRAS CRC
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with MVASI® and FOLFIRI and in Combination with MVASI® and FOLFOX in Subjects with Advanced Colorectal Cancer with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol M)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph2 Epidemi Colon Cancer
View
Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)
Indication:
Colon Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II/III
Title:
Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b
View
Description: (20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract
View
Description: A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II/III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1b/3 Bema + Nivo Gastric GEJ FGFR2b
View
Description: (20210098) A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
Indication:
Gastric Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1b AhRi BAY 2416964 + Pembro ST
View
Description: An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC
View
Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Hematologic
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Leukemia
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph1 Splicing Mod H3B-8800 MDS AML & CML
View
Description: An Open-label Multicenter Phase 1 Trial to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia (H3B-8800-G000-101)
Indication:
Leukemia
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)
View
Description: D9103C00001: A Phase III Randomized Placebo-controlled Double-blind Multi-center International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR PH3 EGFRm stage2/3b NSCLC
View
Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph2 Nap r/r NSCLC
View
Description: NT-NAP-102-1: PHASE 2a OPEN-LABEL MULTICENTER TRIAL OF NAPTUMOMAB ESTAFENATOX (NAP) IN COMBINATION WITH DOCETAXEL FOLLOWING OBINUTUZUMAB PRETREATMENT IN SUBJECTS WITH CHECKPOINT INHIBITOR PRETREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1b AhRi BAY 2416964 + Pembro ST
View
Description: An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC)(VS-6766-202)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph1b AMG 510 in Combo NSCLC KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Carboplatin and Pemetrexed; with Docetaxel; or with Carboplatin and Paclitaxel in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol F)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1b Sotora NSCLC KRAS p.G12C Brain Met
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) with KRAS p.G12C Mutation with Brain Metastases (CodeBreak 101 Subprotocol G)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1b AMG510 + Pembro NSCLC KRAS G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Pembrolizumab in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC) With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol I)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
View
Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
STAR Ph3 Ami Laz EGFR-mut NSCLC
View
Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Biomarker status NSCLC
View
Description: MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
View
Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
Indication:
Lung Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I/II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph3 LOXO-305 vs PC of BTK in MCL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph3 LOXO-305 vs. InvChoice in CLL/SLL
View
Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph2 Lonca-R DLBCL
View
Description: A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph2 Epco r/r B-Cell Lymph out pt
View
Description: A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
Indication:
Lymphomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)
Indication:
Melanoma
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Melanoma
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1 Splicing Mod H3B-8800 MDS AML & CML
View
Description: An Open-label Multicenter Phase 1 Trial to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia (H3B-8800-G000-101)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
PH3 Dara/Len vs Len NDMM
View
Description: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
Indication:
Myelomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph2 Dara Lena Dexa (DRd) MM I
View
Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)
Indication:
Myelomas
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Neuroendocrine Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph1 SGN-TGT Advanced Malignancies
View
Description: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies (SGNTGT-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
STAR Ph2 VS-6766 Fak-Inhib LGSOC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph3 CAM2029 Lanreo ATG GEP-NET
View
Description: A RANDOMIZED MULTI-CENTER OPEN-LABEL ACTIVE-CONTROLLED PHASE 3 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF OCTREOTIDE SUBCUTANEOUS DEPOT (CAM2029) VERSUS OCTREOTIDE LAR OR LANREOTIDE ATG IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (HS-19-657)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
STAR PH3 Abi+/-Capi mHSPC CAPItello-281
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR PH3 Nirap Abira HRR mCSPC
View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
PH3 Place Capi+ Doce Place+ Doce mCRPC
View
Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (D361EC00001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
Ph2 Epidemi Colon Cancer
View
Description: Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II/III
Title:
Ph3 Tivo +Nivo RCC prior ICI
View
Description: TiNivo-2: A Phase 3 Randomized Controlled Multicenter Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor (AV-951-20-304)
Indication:
Renal Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I/II
Title:
Ph2 Tumor-Agnostic Precision TAPISTRY
View
Description: TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph1b AMG 510 +RMC-4630 ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol C)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1b AMG 510 Pani FOLFIRI ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability and Efficacy of Sotorasib in Combination with Panitumumab and in Combination with Panitumumab and FOLFIRI in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
Ph1b AMG 510 + Palboc ST KRAS p.G12C
View
Description: 20190135: A Phase 1b Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of Sotorasib in Combination with Palbociclib in Subjects with Advanced Solid Tumors with KRAS p.G12C mutation (CodeBreak 101 Subprotocol J)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II
Title:
Ph1b AhRi BAY 2416964 + Pembro ST
View
Description: An open-label Phase 1b dose escalation and expansion study to evaluate the safety tolerability maximum tolerated or administered dose pharmacokinetics pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors (BAY 2416964 / 21343)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: I
Title:
A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (STELLAR study)
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: III
Title:
EF-32 (TRIDENT): A PIVOTAL RANDOMIZED, OPEN-LABELSTUDY OF OPTUNE® (TTFIELDS, 200KHZ) CONCOMITANT WITHRADIATION THERAPY AND TEMOZOLOMIDE FOR THETREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Title:
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE).
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Title:
GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer.
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Title:
A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Title:
A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma
Indication:
Brain Cancer
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Title:
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations
Indication:
Solid Tumors
Location:
Texas Oncology-Austin Midtown Sarcoma and Orthopedic Oncology
Phase: II